726174-45-4

Basic information

• Product Name: ethyl (5-bromo-1H-indol-1-yl)acetate
• Synonyms: ethyl (5-bromo-1H-indol-1-yl)acetate;(5-BROMO-1H-INDOL-1-YL)-ACETIC ACID ETHYL ESTER
• CAS NO: 726174-45-4
• Molecular Formula: C12H12BrNO2
• Molecular Weight: 282.13318
• Mol File: 726174-45-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl (5-bromo-1H-indol-1-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl (5-bromo-1H-indol-1-yl)acetate(726174-45-4)
• EPA Substance Registry System: ethyl (5-bromo-1H-indol-1-yl)acetate(726174-45-4)

Safety Data

• Hazardous Substances Data: 726174-45-4(Hazardous Substances Data)

Upstream product

• 10075-50-0 5-bromo-1H-indole 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 148366-28-3 1-(2-Hydroxyethyl)-5-bromoindole 
• 937621-97-1 2-(5-bromo-1H-indol-1-yl)acetic acid 
• 1351767-69-5 C₂₅H₂₅BrF₄N₂O₅ 
• 1351767-61-7 C₂₅H₂₃BrF₄N₂O₅ 
• 1351767-53-7 (S)-3-(2-(5-bromo-1H-indol-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 
• 1351767-73-1 C₂₅H₂₇BrF₂N₂O₅ 
• 1351767-65-1 C₂₅H₂₅BrF₂N₂O₅ 
• 1351767-57-1 (S)-3-(2-(5-bromo-1H-indol-1-yl)acetamido)-5-(2,6-difluorophenoxy)-4-oxopentanoic acid 
• 945549-22-4 C₁₈H₂₄BNO₄ 
• 1423703-51-8 C₁₈H₁₆BrNO₂ 
• 1423703-54-1 C₂₄H₂₈BNO₄ 
• 1423691-89-7 C₃₁H₂₈ClN₃O₄S 
• 1423685-36-2 C₂₉H₂₄ClN₃O₄S 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.